Title:
THERAPEUTIC AGENT FOR BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2022/025150
Kind Code:
A1
Abstract:
Disclosed is a therapeutic agent for breast cancer, said therapeutic agent comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof that is to be administered in combination with an estrogen receptor antagonist or an aromatase inhibitor.
More Like This:
Inventors:
KAWANO SATOSHI (JP)
MIYANO SAORI (JP)
NISHIBATA KYOKO (JP)
FUKUSHIMA SAYO (JP)
MIYANO SAORI (JP)
NISHIBATA KYOKO (JP)
FUKUSHIMA SAYO (JP)
Application Number:
PCT/JP2021/028008
Publication Date:
February 03, 2022
Filing Date:
July 29, 2021
Export Citation:
Assignee:
EISAI R&D MAN CO LTD (JP)
International Classes:
A61K31/4545; A61K31/138; A61K31/4196; A61K31/565; A61K31/5685; A61K31/58; A61K45/00; A61P15/00; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| WO2017104739A1 | 2017-06-22 | |||
| WO2019189241A1 | 2019-10-03 |
Foreign References:
| JP2015505562A | 2015-02-23 | |||
| US20140235614A1 | 2014-08-21 | |||
| US20180015079A1 | 2018-01-18 | |||
| US20180303817A1 | 2018-10-25 | |||
| US20170217935A1 | 2017-08-03 |
Other References:
MIYANO, WATANABE, SAORI ET AL.: "E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models", MOLECULAR CANCER THERAPEUTICS, vol. 15, no. 11, 2016, pages 2630 - 2639, XP055497036, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-16-0261
KATOH, MASARU: "Fibroblast growth factor receptors as treatment targets in clinical oncology", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 16, no. 2, 2019, pages 105 - 122, XP036705943, ISSN: 1759-4774, DOI: 10.1038/s41571-018-0115-y
MUSOLINO, A. ET AL.: "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR +, HER2- breast cancer that had progressed during or after prior endocrine therapy", BREAST CANCER RESEARCH, vol. 19, 2017, pages 18, XP055712809, ISSN: 1465-542X, DOI: 10.1186/s13058-017-0807-8
FORMISANO, L. ET AL.: "Association of FGFR1 with ERa maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer", CLINICAL CANCER RESEARCH, vol. 23, no. 20, 2017, pages 6138 - 6150, XP055712806, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-1232
QUINTELA-FANDINO, M. ET AL.: "Nintedanibplus letrozole in early breast cancer: a phase O/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition", BREAST CANCER RESEARCH, vol. 21, 2019, pages 69, XP055905408, ISSN: 1465-542X
SECKL MICHAEL, BADMAN PHILIP DAVID, LIU XINXUE, MACPHERSON IAIN R., ZUBAIRI ISHTIAQ HUSAIN, BAIRD RICHARD D., GARCIA-CORBACHO JAVI: "RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15_suppl, 20 May 2017 (2017-05-20), US , pages 1059, XP093010667, ISSN: 0732-183X, DOI: 10.1200/JCO.2017.35.15_suppl.1059
HOWELL ET AL.: "Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial", JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 9, 2004, pages 1605 - 1613
DEEKS ET AL.: "Exemestane A Review of its Use in Postmenopausal Women with Breast Cancer", DRUGS, vol. 69, no. 7, 2009, pages 889 - 918
See also references of EP 4151212A4
KATOH, MASARU: "Fibroblast growth factor receptors as treatment targets in clinical oncology", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 16, no. 2, 2019, pages 105 - 122, XP036705943, ISSN: 1759-4774, DOI: 10.1038/s41571-018-0115-y
MUSOLINO, A. ET AL.: "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR +, HER2- breast cancer that had progressed during or after prior endocrine therapy", BREAST CANCER RESEARCH, vol. 19, 2017, pages 18, XP055712809, ISSN: 1465-542X, DOI: 10.1186/s13058-017-0807-8
FORMISANO, L. ET AL.: "Association of FGFR1 with ERa maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer", CLINICAL CANCER RESEARCH, vol. 23, no. 20, 2017, pages 6138 - 6150, XP055712806, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-1232
QUINTELA-FANDINO, M. ET AL.: "Nintedanibplus letrozole in early breast cancer: a phase O/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition", BREAST CANCER RESEARCH, vol. 21, 2019, pages 69, XP055905408, ISSN: 1465-542X
SECKL MICHAEL, BADMAN PHILIP DAVID, LIU XINXUE, MACPHERSON IAIN R., ZUBAIRI ISHTIAQ HUSAIN, BAIRD RICHARD D., GARCIA-CORBACHO JAVI: "RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15_suppl, 20 May 2017 (2017-05-20), US , pages 1059, XP093010667, ISSN: 0732-183X, DOI: 10.1200/JCO.2017.35.15_suppl.1059
HOWELL ET AL.: "Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial", JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 9, 2004, pages 1605 - 1613
DEEKS ET AL.: "Exemestane A Review of its Use in Postmenopausal Women with Breast Cancer", DRUGS, vol. 69, no. 7, 2009, pages 889 - 918
See also references of EP 4151212A4
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: